An improved model for fragment-based lead generation at AstraZeneca.

Modest success rates in fragment-based lead generation (FBLG) projects at AstraZeneca (AZ) prompted operational changes to improve performance. In this review, we summarize these changes, emphasizing the construction and composition of the AZ fragment library, screening practices and working model. We describe the profiles of the screening method for specific fragment subsets and statistically assess our ability to follow up on fragment hits through near-neighbor selection. Performance analysis of our second-generation fragment library (FL2) in screening campaigns illustrates the complementary nature of flat and 3D fragments in exploring protein-binding pockets and highlights our ability to deliver fragment hits using multiple screening techniques for various target classes. The new model has had profound impact on the successful delivery of lead series to drug discovery projects.

[1]  P. Brennan,et al.  The lipids ofMycobacterium tuberculosis BCG: Fractionation, composition, turnover and the effects of isoniazid , 1970, Irish journal of medical science.

[2]  R. Goodnow.  A Handbook for DNA-Encoded Chemistry: Theory and Applications for Exploring Chemical Space and Drug Discovery , 2014 .

[3]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[4]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[5]  A. Leach,et al.  Molecular complexity and fragment-based drug discovery: ten years on. , 2011, Current opinion in chemical biology.

[6]  P. Clemons,et al.  Route to three-dimensional fragments using diversity-oriented synthesis , 2011, Proceedings of the National Academy of Sciences.

[7]  Roderick E. Hubbard,et al.  Lessons for fragment library design: analysis of output from multiple screening campaigns , 2009, J. Comput. Aided Mol. Des..

[8]  Philip M. Dean,et al.  Molecular surface-volume and property matching to superpose flexible dissimilar molecules , 1995, J. Comput. Aided Mol. Des..

[9]  Tomas Fex,et al.  Weak affinity chromatography as a new approach for fragment screening in drug discovery. , 2011, Analytical biochemistry.

[10]  N. Blomberg,et al.  An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. , 2007, Current topics in medicinal chemistry.

[11]  Monya Baker,et al.  Fragment-based lead discovery grows up , 2012, Nature Reviews Drug Discovery.

[12]  Binh Vu,et al.  Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor. , 2013, ACS medicinal chemistry letters.

[13]  C. Murray,et al.  The rise of fragment-based drug discovery. , 2009, Nature chemistry.

[14]  Peter J. Tonge,et al.  The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  C. Bevan,et al.  A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. , 2000, Analytical chemistry.

[16]  이연수.  Functional genomics reveal that the serine synthesis pathway is essential in breast cancer , 2011 .

[17]  Andrew Pannifer,et al.  Using fragment-based technologies to target protein-protein interactions. , 2012, Current pharmaceutical design.

[18]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[19]  Karl A. Walter,et al.  ChemInform Abstract: Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR. , 1997 .

[20]  James E. J. Mills,et al.  Design of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics , 2011, J. Comput. Aided Mol. Des..

[21]  Jean M. Severin,et al.  Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR , 1997 .

[22]  Nathan Brown,et al.  Plane of Best Fit: A Novel Method to Characterize the Three-Dimensionality of Molecules , 2012, J. Chem. Inf. Model..

[23]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[24]  J. Andrew Grant,et al.  Small Molecule Shape-Fingerprints , 2005, J. Chem. Inf. Model..

[25]  Adrian Whitty,et al.  The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.

[26]  Gerhard Klebe,et al.  Comparison of Automatic Three-Dimensional Model Builders Using 639 X-ray Structures , 1994, J. Chem. Inf. Comput. Sci..

[27]  A. Kalgutkar,et al.  Drug discovery for a new generation of covalent drugs , 2012, Expert opinion on drug discovery.

[28]  Wolfgang H. B. Sauer,et al.  Molecular Shape Diversity of Combinatorial Libraries: A Prerequisite for Broad Bioactivity , 2003, J. Chem. Inf. Comput. Sci..

[29]  Niklas Blomberg,et al.  Design of compound libraries for fragment screening , 2009, J. Comput. Aided Mol. Des..

[30]  A. Gavezzotti,et al.  The calculation of molecular volumes and the use of volume analysis in the investigation of structured media and of solid-state organic reactivity , 1983 .

[31]  Andrew P. Turnbull,et al.  Fragment-based drug discovery and protein–protein interactions , 2014 .

[32]  Christopher W Murray,et al.  Efficient exploration of chemical space by fragment-based screening. , 2014, Progress in biophysics and molecular biology.

[33]  M. Uesugi,et al.  [Discovering high-affinity ligands for proteins: SAR by NMR]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[34]  M. Pangalos,et al.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework , 2014, Nature Reviews Drug Discovery.

[35]  Anthony M Giannetti,et al.  Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. , 2008, Journal of medicinal chemistry.

[36]  Nathan Brown,et al.  Fragment-based hit identification: thinking in 3D. , 2013, Drug discovery today.

[37]  Christopher W Murray,et al.  Experiences in fragment-based drug discovery. , 2012, Trends in pharmacological sciences.

[38]  Rutger H A Folmer,et al.  Fragment screening to predict druggability (ligandability) and lead discovery success. , 2011, Drug discovery today.